INSMED INC (INSM) Operating Margin
- Operating margin · 12 months: Value -73.89%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -73.89% | Operating income / revenue. Period ending 2026-06-30. $-840.62M ÷ $1.14B × 100 ≈ -73.89% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -840.62M USD | Operating Income (Loss) |
| Revenue | 1.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 188.22M USD | Cost of Goods and Services Sold |
| Research and development | 860.85M USD | Research and Development Expense |
| Selling, general and administration | 893.59M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-840.62M | $1.14B | $188.22M | $860.85M | $893.59M | -73.89% |
| 2026-03-31 | $-1.15B | $819.56M | $149.08M | $828.00M | $800.88M | -140.56% |
| 2025-12-31 | $-1.25B | $606.42M | $122.94M | $771.09M | $701.17M | -205.59% |
| 2025-09-30 | $-1.16B | $447.02M | $104.87M | $695.91M | $631.20M | -258.92% |
| 2025-06-30 | $-1.00B | $398.11M | $96.67M | $660.30M | $563.75M | -252.41% |
| 2025-03-31 | $-980.89M | $381.03M | $89.56M | $629.86M | $515.56M | -257.43% |
| 2024-12-31 | $-878.25M | $363.71M | $85.74M | $598.37M | $461.12M | -241.47% |
| 2024-09-30 | $-826.11M | $342.96M | $78.03M | $555.67M | (m) | -240.88% |
| 2024-06-30 | $-760.35M | $328.61M | $73.57M | $514.01M | (m) | -231.39% |
| 2024-03-31 | $-706.97M | $315.49M | $69.20M | $564.23M | (m) | -224.08% |
| 2023-12-31 | $-709.63M | $305.21M | $65.57M | $571.01M | (m) | -232.51% |
| 2023-09-30 | $-682.83M | $280.81M | $60.20M | $558.75M | (m) | -243.16% |
| 2023-06-30 | $-662.86M | $269.47M | $56.96M | $549.47M | (m) | -245.98% |
| 2023-03-31 | $-515.65M | $257.46M | $56.77M | $441.03M | (m) | -200.28% |
| 2022-12-31 | $-457.32M | $245.36M | $55.13M | $397.52M | (m) | -186.39% |
| 2022-09-30 | $-404.92M | $242.18M | $55.34M | $349.11M | (m) | -167.20% |
| 2022-06-30 | $-380.84M | $221.21M | $52.06M | $319.58M | (m) | -172.16% |
| 2022-03-31 | $-381.09M | $201.35M | $46.50M | $295.71M | (m) | -189.27% |
| 2021-12-31 | $-375.09M | $188.46M | $44.15M | $272.74M | (m) | -199.03% |
| 2021-09-30 | $-370.55M | $173.75M | $41.73M | $264.21M | (m) | -213.27% |
| 2021-06-30 | $-323.16M | $170.64M | $42.16M | $235.27M | (m) | -189.38% |
| 2021-03-31 | $-288.71M | $167.77M | $41.28M | $206.36M | (m) | -172.09% |
| 2020-12-31 | $-265.23M | $164.41M | $39.87M | $181.16M | (m) | -161.32% |
| 2020-09-30 | $-217.78M | $168.71M | $37.72M | $145.97M | (m) | -129.09% |
| 2020-06-30 | $-218.04M | $163.95M | $33.53M | $138.90M | (m) | -132.99% |
| 2020-03-31 | $-226.09M | $151.43M | $28.50M | $136.69M | (m) | -149.31% |
| 2019-12-31 | $-235.25M | $136.47M | $24.21M | $131.71M | (m) | -172.38% |
| 2019-09-30 | $-275.88M | $100.59M | $17.93M | $139.01M | (m) | -274.26% |
| 2019-06-30 | $-303.38M | $61.71M | $11.49M | $144.20M | (m) | -491.63% |
| 2019-03-31 | $-314.10M | $31.74M | $6.57M | $146.39M | (m) | -989.68% |
| 2018-12-31 | $-307.34M | $9.84M | $2.42M | $145.28M | (m) | -3124.94% |
| 2018-09-30 | $-284.97M | $0.00 | (m) | $139.31M | (m) | (m) |
| 2018-06-30 | $-245.07M | $0.00 | (m) | $126.44M | (m) | (m) |
| 2018-03-31 | $-215.70M | $0.00 | (m) | $117.59M | (m) | (m) |
| 2017-12-31 | $-188.92M | $0.00 | (m) | $109.75M | (m) | (m) |
| 2017-09-30 | $-190.62M | (m) | (m) | $130.67M | (m) | (m) |
| 2017-06-30 | $-183.68M | (m) | (m) | $127.43M | (m) | (m) |
| 2017-03-31 | $-176.30M | (m) | (m) | $124.43M | (m) | (m) |
| 2016-12-31 | $-173.40M | (m) | (m) | $122.72M | (m) | (m) |
| 2016-09-30 | $-138.94M | (m) | (m) | $87.50M | (m) | (m) |
| 2016-06-30 | $-132.03M | (m) | (m) | $83.28M | (m) | (m) |
| 2016-03-31 | $-123.85M | (m) | (m) | $77.66M | (m) | (m) |
| 2015-12-31 | $-117.49M | (m) | (m) | $74.28M | (m) | (m) |
| 2015-09-30 | $-107.97M | (m) | (m) | $69.43M | (m) | (m) |
| 2015-06-30 | $-101.13M | (m) | (m) | $65.41M | (m) | (m) |
| 2015-03-31 | $-95.99M | (m) | (m) | $62.10M | (m) | (m) |
| 2014-12-31 | $-87.36M | (m) | (m) | $56.29M | (m) | (m) |
| 2014-09-30 | $-79.89M | (m) | (m) | $51.12M | (m) | (m) |
| 2014-06-30 | $-73.33M | (m) | (m) | $48.01M | (m) | (m) |
| 2014-03-31 | $-58.78M | (m) | (m) | $45.30M | (m) | (m) |
| 2013-12-31 | $-55.02M | $11.50M | (m) | $44.28M | (m) | -478.39% |
| 2013-09-30 | $-55.26M | $11.50M | (m) | $46.24M | (m) | -480.51% |
| 2013-06-30 | $-47.77M | $11.50M | (m) | $39.86M | (m) | -415.39% |
| 2013-03-31 | $-49.48M | (m) | (m) | $35.38M | (m) | (m) |
| 2012-12-31 | $-42.44M | $0.00 | (m) | $29.78M | (m) | (m) |
| 2012-09-30 | $-35.47M | $1.40M | (m) | $24.07M | (m) | -2528.15% |
| 2012-06-30 | $-61.08M | $1.84M | (m) | $25.46M | (m) | -3322.96% |
| 2012-03-31 | $-61.57M | $2.82M | (m) | $26.64M | (m) | -2186.36% |
| 2011-12-31 | $-61.72M | $4.42M | (m) | $27.92M | (m) | -1397.31% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-8.09M | $6.92M | (m) | $4.76M | (m) | -116.92% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-8.67M | $10.37M | (m) | $9.21M | (m) | -83.62% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |